102 related articles for article (PubMed ID: 26878852)
1. Complete 1H, 15N and 13C assignment of trappin-2 and 1H assignment of its two domains, elafin and cementoin.
Loth K; Alami SA; Habès C; Garrido S; Aucagne V; Delmas AF; Moreau T; Zani ML; Landon C
Biomol NMR Assign; 2016 Apr; 10(1):223-6. PubMed ID: 26878852
[TBL] [Abstract][Full Text] [Related]
2. Secretory leukocyte protease inhibitor (SLPI) is, like its homologue trappin-2 (pre-elafin), a transglutaminase substrate.
Baranger K; Zani ML; Labas V; Dallet-Choisy S; Moreau T
PLoS One; 2011; 6(6):e20976. PubMed ID: 21687692
[TBL] [Abstract][Full Text] [Related]
3. Structural and antimicrobial properties of human pre-elafin/trappin-2 and derived peptides against Pseudomonas aeruginosa.
Bellemare A; Vernoux N; Morin S; Gagné SM; Bourbonnais Y
BMC Microbiol; 2010 Oct; 10():253. PubMed ID: 20932308
[TBL] [Abstract][Full Text] [Related]
4. Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases.
Zani ML; Baranger K; Guyot N; Dallet-Choisy S; Moreau T
Protein Sci; 2009 Mar; 18(3):579-94. PubMed ID: 19241385
[TBL] [Abstract][Full Text] [Related]
5. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family.
Moreau T; Baranger K; Dadé S; Dallet-Choisy S; Guyot N; Zani ML
Biochimie; 2008 Feb; 90(2):284-95. PubMed ID: 17964057
[TBL] [Abstract][Full Text] [Related]
6. Proteolytic susceptibility of the serine protease inhibitor trappin-2 (pre-elafin): evidence for tryptase-mediated generation of elafin.
Guyot N; Zani ML; Berger P; Dallet-Choisy S; Moreau T
Biol Chem; 2005 Apr; 386(4):391-9. PubMed ID: 15899702
[TBL] [Abstract][Full Text] [Related]
7. Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed "cementoin".
Nara K; Ito S; Ito T; Suzuki Y; Ghoneim MA; Tachibana S; Hirose S
J Biochem; 1994 Mar; 115(3):441-8. PubMed ID: 7914520
[TBL] [Abstract][Full Text] [Related]
8. Elafin and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase.
Guyot N; Zani ML; Maurel MC; Dallet-Choisy S; Moreau T
Biochemistry; 2005 Nov; 44(47):15610-8. PubMed ID: 16300411
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of the inhibition of neutrophil proteinases by recombinant elafin and pre-elafin (trappin-2) expressed in Pichia pastoris.
Zani ML; Nobar SM; Lacour SA; Lemoine S; Boudier C; Bieth JG; Moreau T
Eur J Biochem; 2004 Jun; 271(12):2370-8. PubMed ID: 15182352
[TBL] [Abstract][Full Text] [Related]
10. Localization of porcine trappin-2 (SKALP/elafin) in trachea and large intestine by in situ hybridization and immunohistochemistry.
Suzuki Y; Furukawa M; Abe J; Kashiwagi M; Hirose S
Histochem Cell Biol; 2000 Jul; 114(1):15-20. PubMed ID: 10959818
[TBL] [Abstract][Full Text] [Related]
11. The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function.
Baranger K; Zani ML; Chandenier J; Dallet-Choisy S; Moreau T
FEBS J; 2008 May; 275(9):2008-20. PubMed ID: 18341586
[TBL] [Abstract][Full Text] [Related]
12. Protection of lung epithelial cells from protease-mediated injury by trappin-2 A62L, an engineered inhibitor of neutrophil serine proteases.
Tanga A; Saidi A; Jourdan ML; Dallet-Choisy S; Zani ML; Moreau T
Biochem Pharmacol; 2012 Jun; 83(12):1663-73. PubMed ID: 22465040
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human neutrophil elastase-induced acute lung injury in hamsters by recombinant human pre-elafin (trappin-2).
Tremblay GM; Vachon E; Larouche C; Bourbonnais Y
Chest; 2002 Feb; 121(2):582-8. PubMed ID: 11834675
[TBL] [Abstract][Full Text] [Related]
14. The WAP protein Trappin-2/Elafin: a handyman in the regulation of inflammatory and immune responses.
Verrier T; Solhonne B; Sallenave JM; Garcia-Verdugo I
Int J Biochem Cell Biol; 2012 Aug; 44(8):1377-80. PubMed ID: 22634606
[TBL] [Abstract][Full Text] [Related]
15. Elafin and its precursor trappin-2: What is their therapeutic potential for intestinal diseases?
Deraison C; Bonnart C; Langella P; Roget K; Vergnolle N
Br J Pharmacol; 2023 Jan; 180(2):144-160. PubMed ID: 36355635
[TBL] [Abstract][Full Text] [Related]
16. Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract.
Ghosh M; Shen Z; Fahey JV; Cu-Uvin S; Mayer K; Wira CR
Immunology; 2010 Feb; 129(2):207-19. PubMed ID: 19824918
[TBL] [Abstract][Full Text] [Related]
17. Identification and sequence analysis of two new members of the SKALP/elafin and SPAI-2 gene family. Biochemical properties of the transglutaminase substrate motif and suggestions for a new nomenclature.
Zeeuwen PL; Hendriks W; de Jong WW; Schalkwijk J
J Biol Chem; 1997 Aug; 272(33):20471-8. PubMed ID: 9252357
[TBL] [Abstract][Full Text] [Related]
18. Oxidized elafin and trappin poorly inhibit the elastolytic activity of neutrophil elastase and proteinase 3.
Nobar SM; Zani ML; Boudier C; Moreau T; Bieth JG
FEBS J; 2005 Nov; 272(22):5883-93. PubMed ID: 16279952
[TBL] [Abstract][Full Text] [Related]
19. 1H, 15N and 13C assignments of the N-terminal domain of the Mediator complex subunit MED26.
Peruzzini R; Lens Z; Verger A; Dewitte F; Ferreira E; Baert JL; Villeret V; Landrieu I; Cantrelle FX
Biomol NMR Assign; 2016 Apr; 10(1):233-6. PubMed ID: 26861138
[TBL] [Abstract][Full Text] [Related]
20. SLPI and trappin-2 as therapeutic agents to target airway serine proteases in inflammatory lung diseases: current and future directions.
Zani ML; Tanga A; Saidi A; Serrano H; Dallet-Choisy S; Baranger K; Moreau T
Biochem Soc Trans; 2011 Oct; 39(5):1441-6. PubMed ID: 21936830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
